Beskrywing

The urothelial carcinoma (UC) drug market in China in terms of revenue is set to grow by US$ 1 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 27.6% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for urothelial carcinoma (UC) drug. The China urothelial carcinoma (UC) drug market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

The report has profiled some of the key players of the market such as BeiGene Ltd., Rongchang Pharmacy Co. Bpk..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the urothelial carcinoma (UC) drug market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Streek: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the China urothelial carcinoma (UC) drug market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the urothelial carcinoma (UC) drug market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Urothelial Carcinoma (UC) Drug Market by Region
4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China
5. Maatskappy profiele
5.1 BeiGene, Bpk.
5.2 Rongchang Pharmacy Co., Bpk.
6. Bylaag
6.1 Oor StrategyHelix
6.2 Vrywaring